Becton Dickinson & Co. Partners with BCAL Diagnostics Limited
Becton Dickinson & Co. (BDX) has partnered with BCAL Diagnostics Limited (BCAL) to launch BREASTEST plus, a non-invasive breast cancer diagnostic test. This partnership is expected to generate first revenues for BCAL.
Key Details
- BREASTEST plus is a non-invasive breast cancer diagnostic test
- BDX has partnered with BCAL Diagnostics Limited to launch the test
- The partnership is expected to generate first revenues for BCAL
Potential Impact on BDX’s Stock Price
The launch of BREASTEST plus may positively impact BDX’s shares, potentially leading to an increase in value. However, the exact impact of this news on BDX’s stock price remains uncertain.
Note
The potential impact of this news on BDX’s stock price is subject to market fluctuations and other external factors.